Skip to main content
Clinical Trials/JPRN-UMIN000020336
JPRN-UMIN000020336
Completed
Phase 3

Clinical trial to evaluate efficacy and safety of apheresis therapy on peripheral arterial disease with critical limb ischemia. - Clinical trial of apheresis therapy on peripheral arterial disease (ASK-005).

Kaneka Corporation0 sites61 target enrollmentDecember 25, 2015

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Peripheral arterial disease
Sponsor
Kaneka Corporation
Enrollment
61
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 25, 2015
End Date
July 8, 2019
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Patients below SPP 20 mmHg at dorsal or planter of foot with ischemic ulcer 2\. Patients with ischemic ulcer above ankle joint 3\. Patients with metatarsal osteomyelitis 4\. Patients planned to undergo major amputation of any lower limb above lisfranc joint 5\. Patients who are unable to refrain from angiotensin converting enzyme inhibitor

Outcomes

Primary Outcomes

Not specified

Similar Trials